Faes Farma (FAE.MC) Saham Harga
Faes Farma Harga
Selama 19 tahun terakhir pendapatan Faes Farma tumbuh 6,5% per tahun, mencapai 610,46 Juta. EUR. Laba per saham tumbuh 2,9% per tahun selama 19 tahun terakhir. Bagi Faes Farma, margin bersih sebesar 13,0% turun dibanding 20,7% beberapa tahun lalu. Pada harga saat ini imbal hasil dividen sekitar 3,71%. Rasio pembayaran sekitar 70% dari laba. Dividen tumbuh 5,5% per tahun selama 19 tahun terakhir. Target harga konsensus 12 bulan untuk Faes Farma adalah 5,61 EUR, sekitar di atas harga saat ini 16,3%. Dari 10 analis, 6 merekomendasikan beli — konsensus keseluruhan Beli.
Harga saham Faes Farma
Akses data ini lewat Eulerpool API
100.000 permintaan/bulan gratis · tanpa kartu
Model bisnis dan analisis saham Faes Farma
Pertanyaan yang sering diajukan tentang saham Faes Farma
The business model of Faes Farma SA is focused on the research, development, manufacture, and commercialization of pharmaceutical products. The company specializes in the areas of prescription drugs, hospital medications, and non-prescription drugs. Faes Farma SA operates through a diversified portfolio, catering to various therapeutic areas such as respiratory, dermatology, allergy, and gastrointestinal disorders. The company aims to provide innovative and effective solutions to improve people's health and quality of life. Faes Farma SA's commitment to scientific excellence, strategic partnerships, and continuous product development enables it to meet the evolving needs of patients worldwide.
Faes Farma SA is primarily active in the pharmaceutical industry.
Some of the main competitors of Faes Farma SA in the market include pharmaceutical companies like Grupo Ferrer Internacional, Laboratorios Rubió, Almirall, and Laboratorios Normon.
Faes Farma SA is a leading pharmaceutical company with a rich history and strong background. Established in 1933, Faes Farma has grown steadily over the years to become a key player in the healthcare industry. The company specializes in the research, development, manufacturing, and commercialization of innovative drugs and health products. With a primary focus on respiratory, allergy, and anti-inflammatory treatments, Faes Farma has built a solid reputation for delivering high-quality and effective pharmaceutical solutions. Through continuous innovation and strategic partnerships, the company has successfully expanded its global presence and has become a trusted name in the pharmaceutical sector.
Faes Farma SA, a leading pharmaceutical company, has achieved several significant milestones throughout its history. One notable milestone is the successful development and commercialization of innovative pharmaceutical products. The company has also expanded its market reach globally, establishing a strong presence in various countries. Furthermore, Faes Farma SA has demonstrated continuous growth through strategic partnerships, collaborations, and acquisitions. These milestones reflect the company's commitment to advancing healthcare and delivering quality solutions to customers worldwide. With its relentless dedication and industry expertise, Faes Farma SA has emerged as a prominent player in the pharmaceutical sector, consistently achieving commendable results.
Faes Farma SA is primarily present in Spain and Portugal.
Faes Farma SA represents values and a corporate philosophy centered on innovation, excellence, and commitment to improving healthcare. With a focus on research and development, the company strives to develop high-quality pharmaceutical products that address unmet medical needs. With a long history dating back to 1933, Faes Farma SA emphasizes ethical business practices and sustainable growth. By leveraging its scientific expertise and state-of-the-art technologies, the company aims to provide effective therapies and contribute to the well-being of patients worldwide. Faes Farma SA's dedication to innovation and patient-centric approach makes it a reputable player in the pharmaceutical industry.
Analis saat ini menetapkan target harga rata-rata 5,36 EUR untuk saham Faes Farma (median: 5,61 EUR), yaitu +11,0 % terhadap harga terbaru. Konsensus didasarkan pada 10 peringkat analis.
10 analis saat ini menilai saham Faes Farma: 6 merekomendasikan beli, 3 tahan, dan 1 jual. Untuk 2026, analis memperkirakan Faes Farma menghasilkan pendapatan 758,51 Juta. EUR dan laba per saham 0,31 EUR.
Saham Faes Farma (FAE.MC) tercatat di 7 bursa, termasuk: London (0K9H.L), Frankfurt (FFEA.F), München (FFEA.MU), Düsseldorf (FFEA.DU), Madrid (FAE.MC).
Faes Farma SA is a leading pharmaceutical company specializing in the manufacturing and marketing of medicines and medical products. The company was founded in 1933 and is headquartered in Barcelona, Spain. Faes Farma operates in various business areas, including pharmaceutical products, diagnostic and laboratory services, and skincare products. Pharmaceutical products Faes Farma offers a wide range of pharmaceutical products that can be used to treat various diseases and ailments. The company focuses on the development of drugs in the areas of pain medicine, allergology, and respiratory and eye diseases. One outstanding product is Bilastine, an antihistamine used to treat allergic diseases. In 2020, the company generated sales of €136 million with Bilastine. Diagnostic and laboratory services Faes Farma also operates a division for diagnostic and laboratory services. The company offers various tests to detect and treat diseases early. For example, Faes Farma offers a test to determine if a person is suffering from celiac disease. Another example is a test that detects the presence of antibodies against SARS-CoV-2. Skincare products The company also offers a line of skincare products marketed under the brand Bionike. These products have been specifically developed for people with sensitive skin and do not contain questionable ingredients. The product range includes face creams, cleansers, and sunscreens. Faes Farma has a diversified business model based on the development of new products and the expansion into new markets. The company is focused on innovation and invests a significant portion of its sales in research and development every year. Thanks to its innovative capacity and strong market presence, Faes Farma has experienced solid growth in recent years. In 2020, the company had sales of €317.2 million. The size of the company allows for international business expansion. Faes Farma operates in over 80 countries and has a strong presence, particularly in Latin America and Asia.
Pendapatan diperkirakan dari Faes Farma adalah 758,51 Juta. EUR. Angka ini didasarkan pada data keuangan terkini dan mencerminkan kinerja bisnis perusahaan.
Laba diperkirakan dari Faes Farma adalah 96,30 Juta. EUR. Laba bersih mencerminkan profitabilitas perusahaan setelah mengurangi semua biaya.
Rasio harga-terhadap-pendapatan (PER) Faes Farma saat ini adalah 15,60. PER membandingkan harga saham saat ini dengan laba per saham dan membantu investor menilai valuasi saham Faes Farma.
Rasio harga-terhadap-penjualan (PSR) Faes Farma saat ini adalah 1,98. PSR membandingkan kapitalisasi pasar dengan pendapatan tahunan dan berfungsi sebagai metrik valuasi untuk saham Faes Farma.
Skor Kualitas AlleAktien untuk Faes Farma adalah 7/10.
ISIN dari Faes Farma adalah ES0134950F36. ISIN (International Securities Identification Number) adalah identifikasi unik global untuk sekuritas.
WKN dari Faes Farma adalah A0MKAC. WKN (Wertpapierkennnummer) adalah kode identifikasi sekuritas Jerman enam digit.
Ticker dari Faes Farma adalah FAE.MC. Simbol ticker digunakan untuk memperdagangkan saham Faes Farma di bursa saham.
Saham Faes Farma
Kelompok Peer Faes Farma
Faes Farma Ticker
Faes Farma FIGI
Semua metrik fundamental dan analisis mendalam Faes Farma
Analisis saham kami untuk saham Faes Farma mencakup kalkulasi keuangan penting seperti pendapatan, keuntungan, P/E ratio (P/E), P/S ratio (P/S), EBIT, serta informasi tentang dividen. Selain itu, kami juga mengamati aspek-aspek seperti saham, kapitalisasi pasar, utang, ekuitas, dan kewajiban dari Faes Farma. Jika Anda mencari informasi lebih rinci tentang topik-topik ini, kami menawarkan analisis terperinci di subhalaman kami.